IperionX Limited Sponsored ADR (NASDAQ:IPX) Given Consensus Rating of “Moderate Buy” by Analysts

IperionX Limited Sponsored ADR (NASDAQ:IPXGet Free Report) has received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $60.3333.

A number of equities research analysts recently issued reports on the stock. Roth Mkm reaffirmed a “buy” rating on shares of IperionX in a research note on Monday, June 8th. B. Riley Financial dropped their price objective on shares of IperionX from $58.00 to $52.00 and set a “buy” rating for the company in a research note on Friday, March 13th. Alliance Global Partners restated a “buy” rating on shares of IperionX in a report on Tuesday, April 28th. Weiss Ratings restated a “sell (e+)” rating on shares of IperionX in a research report on Tuesday, April 21st. Finally, BTIG Research increased their price target on shares of IperionX from $40.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 5th.

Get Our Latest Report on IperionX

Insider Activity

In related news, CEO Anastasios Arima purchased 110,000 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was purchased at an average price of $4.49 per share, with a total value of $493,900.00. Following the completion of the purchase, the chief executive officer owned 12,316,782 shares of the company’s stock, valued at approximately $55,302,351.18. The trade was a 0.90% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Todd Hannigan acquired 260,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The stock was purchased at an average price of $4.20 per share, with a total value of $1,092,000.00. Following the completion of the acquisition, the chairman directly owned 26,108,334 shares of the company’s stock, valued at $109,655,002.80. This represents a 1.01% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 590,000 shares of company stock valued at $2,571,500.

Institutional Trading of IperionX

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in shares of IperionX during the second quarter worth $66,000. State of Tennessee Department of Treasury acquired a new stake in shares of IperionX in the 4th quarter worth $119,000. DV Equities LLC purchased a new stake in IperionX in the fourth quarter valued at about $178,000. Man Group plc acquired a new stake in IperionX in the fourth quarter worth about $257,000. Finally, DLD Asset Management LP acquired a new stake in IperionX in the first quarter worth about $260,000. 2.76% of the stock is owned by hedge funds and other institutional investors.

IperionX Price Performance

NASDAQ IPX opened at $28.78 on Friday. The company has a current ratio of 4.03, a quick ratio of 4.00 and a debt-to-equity ratio of 0.03. IperionX has a one year low of $21.66 and a one year high of $61.45. The stock has a 50 day moving average price of $34.77 and a 200-day moving average price of $37.73.

IperionX Company Profile

(Get Free Report)

IperionX (NASDAQ: IPX) is a mineral technology company focused on the production and commercialization of high‐purity titanium and zirconium products. The company’s core activities include the development of advanced mineral sands projects and the deployment of proprietary processing technologies aimed at supplying feedstocks to aerospace, defense, additive manufacturing and battery markets.

At the heart of IperionX’s operations is the Stony Creek Project in Virginia, where the company holds significant mineral sands rights.

Featured Articles

Analyst Recommendations for IperionX (NASDAQ:IPX)

Receive News & Ratings for IperionX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IperionX and related companies with MarketBeat.com's FREE daily email newsletter.